Durable humoral immunity and long-term protection induced by a Crimean-Congo hemorrhagic fever virus replicon particle vaccine in mice
A Crimean-Congo hemorrhagic fever virus replicon particle vaccine was evaluated for long-term immunity and efficacy in mice. IgG responses persisted up to 18 months, with similar titers across dosing strategies through 12 months. Protective efficacy reached ≥75% at 6 months (prime-only) and up to 12 months (prime-boost). Booster dosing enhanced antibody avidity, effector function, and improved long-term protection. These findings support durable immunity from single or boosted vaccination.
Authors
- Jessica R. Spengler (ORCID: https://orcid.org/0000-0002-5383-0513)
- Katherine A. Davies
- Elif Karaaslan (ORCID: https://orcid.org/0000-0002-5097-8854)
- Stephen R. Welch (ORCID: https://orcid.org/0000-0002-6905-8521)
- Éric Bergeron (ORCID: https://orcid.org/0000-0003-3398-8628)
- Florine E. M. Scholte (ORCID: https://orcid.org/0000-0003-2110-3087)
- JoAnn D. Coleman-McCray (ORCID: https://orcid.org/0000-0003-0396-2224)
- Christina F. Spiropoulou (ORCID: https://orcid.org/0000-0001-8406-3161)
- Scott D. Pegan (ORCID: https://orcid.org/0000-0002-2958-5319)
- Joel M. Montgomery (ORCID: https://orcid.org/0000-0003-0523-4431)
- Teresa E. Sorvillo (ORCID: https://orcid.org/0000-0003-2943-4040)
- Virginia Aida-Ficken
Institutions
- University of California, Riverside (US)
- Centers for Disease Control and Prevention (US)
- Agricultural Research Service (US)
- United States Department of Agriculture (US)
- CDC Foundation (US)
- Auburn University (US)
Publication Details
- Journal
- npj Vaccines
- Published
- 2025-11-21
- DOI
- https://doi.org/10.1038/s41541-025-01293-9
- Primary Topic
- Viral Infections and Vectors
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Energy
- U.S. Department of Agriculture
- Oak Ridge Associated Universities
- Centers for Disease Control and Prevention
- Oak Ridge Institute for Science and Education
- Agricultural Research Service
- National Institute of Allergy and Infectious Diseases